Get Started. It's Free
or sign up with your email address
Miscellaneous by Mind Map: Miscellaneous

1. Differentiating Agents

1.1. Tretinoin

1.1.1. Differentiation of immature blood cells into functional cells

1.1.1.1. AEs: vitamin A tox, CNs tox

1.2. Arsenic trioxide

1.2.1. Induces differentiation of APL cells

1.2.1.1. AEs: fatigue, heart abnormalities

2. Proteasome Inhibitor

2.1. Cartilzomib

2.1.1. AEs: Anemia, neutropenia, dyspnea, diarrhea

2.2. Ixazomib

2.2.1. AEs: Thrombocytopenia, GI, peripheral neuropathy

2.3. Bortezomib

3. Biological Response and Modifiers and Immune Modulators

3.1. Interferon-alpha

3.1.1. AEs: flu-like, fever, fatigue

3.2. IL-2

4. Antibodies

4.1. As biological response modifiers, promote ADCC

4.1.1. Rituximab

4.1.1.1. AEs: infusion rxn, cardiac arrest, tumor lysis syndrome

4.1.2. Obinutuzumab

4.1.3. Alemtuzumab

4.1.4. Blinatumomab

4.2. Multiple myeloma and immune response modifier

4.2.1. Daratumumab

4.2.1.1. IgG1k mAB against CD38

4.2.2. Elotuzumab

4.2.2.1. Binds SLAM

4.3. Pediatric neuroblastoma

4.3.1. Dinutuximab

4.3.1.1. Chimeric mAB binds GD2

4.4. T-cell modulator

4.4.1. Ipilimumab

4.4.1.1. anti-CTLA4

4.4.1.2. AEs: autoimmune related rxns

4.4.2. Nivolumab

4.4.2.1. anti-PD-1

4.4.3. Pembrolizumab

4.4.3.1. anti-PD-1

4.4.4. Atezolizumab

4.4.4.1. Anti-PDL1 inhibitor

5. PARP Inhibition

5.1. Oliparib

5.1.1. Blocks SSBR in cells

5.1.2. Ovarian cancer

5.2. Rucaparib

5.2.1. Blocks SSBR in cells

5.2.2. Ovarian cancer

5.3. Niraparib

5.3.1. Ovarian, fallopian, peritoneal

5.4. Talazoparib

5.4.1. Breast

6. HIDAC Inhibitors

6.1. Panobinostat

6.1.1. remove acetyl groups from lysine

6.1.2. AEs: diarrhea, cardiac tox, myelosuppression

6.2. Belinostat

6.2.1. remove acetyl groups from lysine

6.3. Tazemetostat

6.3.1. inhibitor of EZH2 histone methyltransferase

7. CDK Inhibitors

7.1. Palbociclib

7.1.1. block cell cycle progression

7.2. Abemaciclib

8. BCL2 Inhibitor

8.1. Venetoclax

8.1.1. AEs: tumor lysis syndrome, neutropenia

9. Extracellular: Antibodies at Growth Factor RTK inhibitors

9.1. Cetuximab

9.1.1. IgG1 type chimeric mAb against EGFR

9.1.2. AEs: infusion rxn, HTN

9.2. Panitumumab

9.2.1. IgG2 type fully human mAb against EGFR

9.3. Bevacizumab

9.3.1. Humanized mAb against VEGF-A

9.4. Necitumumab

9.4.1. mAb against EGFR

9.5. Margetuximab

9.5.1. mAb against HER2

9.5.2. AEs: infusion rn, HTN, delayed tox

9.6. Olaratumab

9.6.1. mAb that blocks PDGFRa

9.7. Ramucirumab

9.7.1. mAb that binds to VEGFR2

10. Intracellular: TK Inhibitors (small molecules)

10.1. Geftinib

10.1.1. AEs: skin rash, diarrhea

10.2. Erlotinib

10.2.1. AEs: same as Getfttinib

10.3. Imatinib

10.3.1. Inhibits at BCr-Ab1 oncoprotein

10.3.2. AEs: N, V, delayed tox

10.4. Dasatinib

10.4.1. Inhibits VCr-Ab1, Src, c-kit, PDGFR-beta

10.5. Nilotinib

10.5.1. Same moa as Dasatinib

10.6. Bosutinib

10.7. Omacetaxine

10.8. Ponatinib

10.8.1. BB warning -- arterial occlusion

10.8.2. AEs: thromboembolism, HF, hepatox

11. Growth Factor Receptor Inhibition

11.1. Aflibercept

11.1.1. Bind VEGF and PGF

11.1.2. AEs: GI, compromised wound healing

11.1.3. BBW: hemorrhage

11.2. Siltuximab

11.2.1. binds to IL-6

12. GPCR Inhibitor

12.1. Vismodegib

12.1.1. activates Hedgehod signaling

12.2. Sonidegib

12.2.1. Inhibits Smo

13. MAP Kinase Signaling

13.1. Serine/threonine kinase inhibitors

13.1.1. Vemurafenib

13.1.2. Dabrafenib

13.2. MEK/ERK Inhibitors

13.2.1. Trametinib

13.2.2. Cobimetinib

13.2.3. Binimetinib

13.2.4. Selumetinib